Serious toxicity associated with continuous nevirapine-based HAART in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Infectious Diseases
• Pharmacology

Background:

• Highly active antiretroviral therapy (HAART) is crucial for managing HIV during pregnancy.
• Understanding the safety profile of specific antiretroviral drugs, like nevirapine (NVP), is essential for optimizing maternal and infant outcomes.
• Nevirapine's use in pregnancy requires careful consideration due to potential toxicities.

Purpose of the Study:

• To evaluate the safety of nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in HIV-positive pregnant women.
• To compare the toxicity rates between NVP-based and non-NVP-based HAART regimens during pregnancy.
• To identify factors associated with antiretroviral drug toxicity in this population.

Main Methods:

• A prospective cohort study was conducted involving HIV-positive pregnant women receiving HAART.
• Demographic and clinical data were collected to assess drug toxicities.
• Multivariate analyses were employed to determine predictors of toxicity.

Main Results:

• Of 103 women on HAART, 54% received NVP-based regimens and 46% received non-NVP-based regimens.
• Toxicities requiring treatment discontinuation occurred in 6 of 56 NVP-exposed women versus 1 of 47 non-NVP-exposed women.
• First-time NVP use was associated with a higher toxicity rate (12.5%) and approached statistical significance as a predictor.

Conclusions:

• Continuous nevirapine (NVP) use during pregnancy was associated with a higher incidence of toxicity.
• All observed NVP-related toxicities occurred in women initiating NVP for the first time during pregnancy.
• These findings highlight the importance of considering prior NVP exposure when prescribing HAART in pregnant individuals.